🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Todo a punto!!!! Encantado de poder coordinar el bloque de #tumoresurologicos en el evento ROVI ONCO HUB con MJosé Juan Enrique Grande joaquim bellmunt Álvaro Pinto

Paper 10 BLADDER Important work by Hamidi et al. who identified four molecular subtypes in urothelial carcinoma with distinct tumor microenvironments, revealed a survival benefit from #atezolizumab for immune and basal tumors, and proposed a digital pathology that predicts

Learning so much from Joshua Meeks on the current status of BCG & ways to accommodate the shortage. Exciting to see trials from Max Kates ECOG-ACRIN Cancer Research Group & Rob Svatek splernerMD @swog, and of course everyone awaiting CREST! #AUC3

The #AUC3 bladder cancer panel about 1L bladder cancer is on fire 🔥! Shilpa Gupta Daniel Petrylak Petros Grivas joaquim bellmunt

✍️ Inscripcions obertes! Recent Advances in Genitourinary Malignancies #RAGM2025 📅 21 de febrer 📌Auditori Biomedicina BCN Organitzat per @hmar_research i dirigit pel Dr. joaquim bellmunt i el Dr. juan pablo fusco ➕Informació 👉 imim.cat/agenda/902/

ctDNA in Bladder Cancer - Don’t miss today at 2:30 PM the Symposium: “Panning for Gold: The Role of ctDNA as a Biomarker for Bladder Cancer” #GU25 ASCO Dana-Farber Lank Center for Genitourinary Oncology . Summary at Am Soc Clin Oncol Educ Book doi.org/10.1200/EDBK-2…

Eye opening presentation from Nimira Alimohamed on the potential impact of ctDNA on perioperative management of MIBC! ASCO #GU25 joaquim bellmunt Bernadett Szabados OncoAlert

How can urine and plasma liquid biopsy be used across the spectrum of urothelial carcinoma? Terrific discussion by Gillian Vandekerkhove ASCO #GU25 joaquim bellmunt Bernadett Szabados OncoAlert

✍️ Inscripciones abiertas! Recent Advances in Genitourinary Malignancies #RAGM2025 📅 21 de febrero📌Auditorio Biomedicina BCN Organitzado por @hmar_research y dirigido por el Dr. joaquim bellmunt y el Dr. juan pablo fusco ➕Información 👉 researchmar.net/agenda/902/

A study by HMar Research Institute, published in Nature Communications, identifies predictive markers of response to #immunotherapy in #bladdercancer through large-scale #data analysis #oncologia UPF Barcelona Bioinformatics GRIB hospitaldelmar.cat/en/noticies/vi…

💫 Our paper “Predicting immunotherapy response of adv bladder ca through a metaanalysis of six independent cohorts” is out today at Nature Commun. Data of 707 adv bladder ca pts treated with anti-PD-1/anti-PD-L1 to build highly accurate predictive models. rdcu.be/eaDie

Dr. joaquim bellmunt and Dr. Joan Albanell, opening the #RAGM2025 Congress First round table 1 to address topics about #prostaticCancer #TalentMAR Biomedicina BCN juan pablo fusco

Serial ctDNA testing identifies #BladderCancer patients who may avoid adjuvant therapy. joaquim bellmunt Dana-Farber joins Zach Klaassen Georgia Cancer Center to discuss findings from the #IMvigor011 study on circulating tumor DNA monitoring in high-risk muscle-invasive bladder cancer

Two amigos on a mission to conquer kidney cancer!! ⁦Toni Choueiri, MD⁩ ⁦Dana-Farber⁩ ⁦Dana-Farber Lank Center for Genitourinary Oncology⁩ ⁦Romee Lab⁩ #NK #immunotherapy #KidneyCancer

Thoroughly enjoyed my day and conversations at Dana-Farber Lank Center for Genitourinary Oncology Kent Mouw Atish Choudhury, MD PhD Stephanie Berg Matthew Mossanen joaquim bellmunt Eli Van Allen Toni Choueiri, MD discussing the latest in #bladdercancer research and clinical trials. Thank you for the invitation and your hospitality!

💫03/28, 2025, FDA approved Neodj durvalumab with Gem and CDDP followed by durva as adj tt following RC in MIBC. The major efficacy outcome event-free survival (EFS) by BICR. OS was an additional efficacy outcome. First time improvement in OS in a periop trial.✨@bladderCancerUS

Serial ctDNA testing identifies #BladderCancer patients who may avoid adjuvant therapy. joaquim bellmunt Dana-Farber joins Zach Klaassen Georgia Cancer Center to discuss findings from the #IMvigor011 study on circulating tumor DNA monitoring in high-risk muscle-invasive bladder cancer

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

I’ll be at #ASCO25 to discuss abst 4596: “A phase II prospective, open-label, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive NMIBC pts: SSANTROP (APRO07-2022)”. Join 9am 06/02/25 HallA #: 396 meetings.asco.org/abstracts-pres… Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber News

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉LBA4513: Dr #VitalyMargulis presenting padeliporfin vascular targeted photodynamic therapy (VTP) for low grade UTUC from ph3 #ENLIGHTED 🩺Clinical implications: - #ENLIGHTED shows #VTP has early efficacy and safety supporting accrual